Die Brachiopoen des Callovien im zentralen Nordwestschweizer Jura

Im Rahmen einer lithologischen, biostratigraphischen und faziellen Neubearbeitung des Callovien im zentralen Nordwestschweizer Jura werden auch verschiedene Faunenelemente berücksichtigt und untersucht. In dieser Arbeit wird im ersten Teil die Fazies von vier lithologischen Einheiten (Châtillon-, Bollement-, Herznach- und Graitery-Member) vorgestellt, die Brachiopoden führen. Diese sind im zweiten Teil näher beschrieben. Dabei konnten im Untersuchungsgebiet 21 Arten festgestellt werden: 6 Rhynchonelliden, 15 Terebratuliden (davon 7 Terebratulidinen und 8 Terebratellidinen). 8 Spezies sind nicht nur im Untersuchungsgebiet erstmals nachgewiesen worden, sie sind für das ganze Gebiet der Schweiz neu: Fortunella? acutiloba, Septaliphoria orbignyana, Dictyothyris smithi, orsoplicathyris flexuosa, Antiptychina bivallata, Aulacothyris hypocirta, Digonella cf. pseudoantiplecta, „Zeilleria“ cf. biappendiculata.

Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99)

BACKGROUND: We evaluated previously established regimens of capecitabine plus vinorelbine in older patients with advanced breast cancer stratified for presence versus absence of bone metastases. PATIENTS AND METHODS: Patients > or =65 years who had received no prior chemotherapy for advanced breast cancer received up to six 21-day cycles of vinorelbine 20 mg/m(2) i.v. on days 1 + 8 with oral capecitabine on days 1-14 (1,000 vs. 1,250 mg/m(2) daily in patients with vs. without bone involvement). RESULTS: Median age was 72 years in patients with bone metastases (n = 47) and 75 years in patients without bone metastases (n = 23). Response rates were 43% (95% confidence interval, CI, 28.3-58.8) and 57% (95% CI = 34.5-76.8), respectively. Median time to progression was 4.3 (95% CI = 3.5-6.0 months) and 7.0 months (CI = 4.1-8.3), respectively. Neutropenia was the most common toxicity, with grade 3/4 occurring in 43 and 39%, respectively. Pulmonary embolism was seen in 5 and grade 3 thrombosis in 3 patients. Other toxicities were mild to moderate. CONCLUSIONS: These regimens of capecitabine and vinorelbine are active and well tolerated in patients with advanced breast cancer > or =65 years. Response rates were comparable to published results. The lower capecitabine doses appeared appropriate given the advanced age, bone involvement and prior radiotherapy.